Cystic Fibrosis (CF) Therapeutics Market- Growth, Trends, and Forecast (2020 - 2025)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 111 Pages | 納期: 2~3営業日

価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.84円
出版日: 2020年08月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 111 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次


Cystic Fibrosis Foundationが発表したデータによると、この遺伝性疾患の発生率は絶えず増加しています。 2019年には、70,000人以上の患者が嚢胞性線維症を患いながら生活しています。患者数が年々増加しているため、効率的かつ効果的な治療薬の需要がさらに高まっています。

潜在的な臨床パイプライン候補薬の増加も、市場の成長を推進すると予想される重要な要因の1つです。さらに、既存の薬剤ポートフォリオで対象患者ベースを拡大するための臨床試験数の急増も、この市場を促進する要因となっています。拡大する研究開発活動は、市場の成長を後押しすると期待されています。パイプラインにある薬剤には、Symdeko(tezacaftor + ivacaftor)、VX-561、ELX-02、ABBV-3067などがあります。

嚢胞性線維症に関する活動に一貫して関与しているCysticFibrosis Worldwide、Cystic Fibrosis Foundation、Cystic Fibrosis Canada、South African Cystic Fibrosis Trust、South African Cystic FibrosisAssociationなどのさまざまな非営利団体の存在も、急増する需要に対応する重要な要素のひとつです。これらの組織は、 嚢胞性線維症のさまざまな治療法を見つけ、著名なプレーヤーによる研究開発活動を支援するために巨額の資金を投資しています。ただし、治療費が高いことが市場の成長を抑制するとみられています。



第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場の推進力
    • 嚢胞性線維症の有病率の増加
    • 政府の手厚い規制
    • 潜在的な臨床パイプライン候補薬の増加
  • 市場の抑制要因
    • ブロックバスターとジェネリック医薬品の特許満了
    • 病気の治療費の高さ
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 薬剤クラス別
    • 膵臓酵素サプリメント
    • 粘液溶解薬
    • 気管支拡張薬
    • CFTR調節薬
  • 投与ルート別
    • 経口薬
    • 吸入薬
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米
    • ブラジル
    • アルゼンチン
    • その他

第6章 競合情勢

  • 企業プロファイル
    • AbbVie Inc.
    • Alaxia
    • Allergan
    • AstraZeneca
    • Beyond Air Inc.
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences Inc.
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd
    • Vertex Pharmaceuticals Incorporated

第7章 市場機会と将来動向

Product Code: 68417

The cystic fibrosis therapeutics market is anticipated to register a CAGR of nearly 9.1% during the forecast period. The increasing prevalence of cystic fibrosis (CF), coupled with the rising treatment rate, is one of the key factors expected to bode well for the market growth for these therapeutics. Moreover, a rising number of initiatives undertaken by nonprofit organizations, an increase in R&D funding by both private and public organizations, and supportive government legislation are some of the crucial factors expected to drive the market in the coming few years.

According to the data published by the Cystic Fibrosis Foundation, the incidence of these hereditary disorders is constantly growing. In 2019, there were more than 70,000 patients are living with cystic fibrosis. Increasing year-on-year growth in the number of patients further results in surging demand for efficient and effective CF therapeutics.

The rising number of potential clinical pipeline candidates is one of the key factors expected to propel the market growth. Moreover, upsurge in the number of clinical trials to expand its target patient base with the existing drug portfolio is also amongst some of the drivers of this market. Growing R&D activities are expected to propel market growth. Some of the pipelined drugs are Symdeko (tezacaftor + ivacaftor), VX-561, ELX-02 and ABBV-3067.

The presence of various nonprofit organizations, such as Cystic Fibrosis Worldwide, Cystic Fibrosis Foundation, Cystic Fibrosis Canada, South African Cystic Fibrosis Trust, and South African Cystic Fibrosis Association, which are consistently involved in the activities related to CF is also one of the pivotal factors that can be accounted for surging demand. These organizations are investing huge amount of funds to find various therapeutics for CF and to support the research and developmental activities by prominent players. However, high cost of the treatment may restrain the growth of the market.

Key Market Trends

CFTR Modulators Dominates the Market and is Expected to Continue to Do the Same during the Forecast Period

CFTR modulators are expected to dominate the cystic fibrosis therapeutics market through the forecast period. This can be attributed to new product launch, high commercial availability, and huge demand for these drugs to treat CF are expected to drive the segment. These modulators are designed to correct the malfunctioning protein made by the CFTR gene. For instance, recently launched ORKAMBI lead the way for segmental growth. This drug class directly cures the underlying cause of the disease.

Thus, the CFTR modulators segment is witnessing a shift toward combination therapies that provide enhanced results to patients. Higher availability, positive results, and reimbursement policies by key players for the target disease are supplementing the growth of the segment. Focus on developing new drugs to address the changing needs of the patients, such as TRIKAFTA and KALYDECO, in the treatment poised to create a significant shift in prescription patterns.

North America Represents the Largest Market and Asia-Pacific is Expected to Register Fastest Growth.

North America is at the forefront of growth in the region and is also an important revenue contributor in the global arena. Heightened awareness of disease remittance therapies among patients, rising prevalence of CF, and high public and private healthcare spending are stimulating the growth of the region. The United States has most of the people affected with CF who are of Caucasian descent. Furthermore, initiatives taken by CF Foundation and Cystic Fibrosis Canada are one of the key reasons that can be accounted for its largest share. Moreover, easy access to quality healthcare, favorable reimbursement policies, strong clinical pipeline, and approval of novel drugs are projected to promote revenue growth in North America.

The Asia-Pacific is likely to witness the fastest growth throughout the forecast period. The growing adoption of the urban lifestyle is leading to expanding the base of patients in the region. This, coupled with increasing healthcare spending, is expected to propel the market in APAC. Favorable regulatory policies for biosimilars are estimated to boost demand for the regional market over the forecast period.

Competitive Landscape

The key players are consistently involved in the development of new or combination of products to treat cystic fibrosis. Investment in the R&D is one of the strategic measures to beat the competition. The key players in this market are AbbVie Inc.; F. Hoffmann-La Roche Ltd; Gilead; Novartis AG; Vertex Pharmaceuticals Inc.; AIT (Advanced Inhalation Therapies); Alaxia; Teva Pharmaceutical Industries Ltd; Merck & Co. Inc.; Alcresta Therapeutics Inc.; Allergan; and AstraZeneca.

The players operating in the market focus on introducing new products to address the changing needs of the patients. For instance, in April 2019, the US Food and Drug Administration (FDA) approved Vertex Pharmaceuticals Incorporated's KALYDECO (ivacaftor) with an aim of expanding the range of treatment options for the millions of children living with cystic fibrosis (CF). This allows physicians to begin treating the underlying cause of CF in eligible infants as young as six months of age for the first time, with the potential to modify the course of the disease.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support



  • 1.1 Study Assumptions
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cystic Fibrosis
    • 4.2.2 Supportive Government Legislation
    • 4.2.3 Increase in Potential Clinical Pipeline Candidates
  • 4.3 Market Restraints
    • 4.3.1 Patent Expiration of Blockbuster and Generic Drugs
    • 4.3.2 High Cost of Disease Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Drug Class
    • 5.1.1 Pancreatic Enzyme Supplements
    • 5.1.2 Mucolytics
    • 5.1.3 Bronchodilators
    • 5.1.4 CFTR Modulators
  • 5.2 By Route of Administration
    • 5.2.1 Oral Drugs
    • 5.2.2 Inhaled Drugs
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.3.5 South America
    • 5.3.6 Brazil
    • 5.3.7 Argentina
    • 5.3.8 Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Alaxia
    • 6.1.3 Allergan
    • 6.1.4 AstraZeneca
    • 6.1.5 Beyond Air Inc.
    • 6.1.6 F. Hoffmann-La Roche Ltd
    • 6.1.7 Gilead Sciences Inc.
    • 6.1.8 Mylan NV
    • 6.1.9 Teva Pharmaceutical Industries Ltd
    • 6.1.10 Vertex Pharmaceuticals Incorporated